Carfilzomib in multiple myeloma

Expert Opinion on Biological Therapy

Volumn 14, Issue 11, 2014, Pages 1685-1699

  Andreu Vieyra, Claudia ^a   Berenson, James R ^a,b,c  

^a Oncotherapeutic   (United States)

^b INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^c MD Inc ^*  (United States)

Author keywords

Carfilzomib; Epoxyketone class; Multiple myeloma; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEASOME; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOMYOPATHY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSPNEA; ELIMINATION HALF-LIFE; ENZYME INHIBITION; FATIGUE; FEVER; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER FAILURE; LUNG COMPLICATION; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); NEOPLASM RECURRENCE, LOCAL; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OLIGOPEPTIDES; PROTEASOME INHIBITORS;

EID: 84911215826     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.953050     Document Type: Article

References (95)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Updated 14 June 2013. Available from: http://seer.cancer.gov/csr/1975-2010
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
3. Jain S, Diefenbach C, Zain J, et al. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid 2011;6:43-57
4. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med 2009;30:191-296
5. O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-91
6. Bennett MK, Kirk CJ. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 2008;11:616-25
7. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generations of peptides presented on most MHC class I molecules. Cell 1994;78:761-71
8. Hideshima T, Anderson KC. Biologic impact of proteasome inhibition in multiple myeloma cells - from the aspects of preclinical studies. Semin Hematol 2012;49:223-7
9. Kale AJ, Moore BS. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem 2012;55:10317-27
10. Cenci S. The proteasome in terminal plasma cell differentiation. Semin Hematol 2012;49:215-22
11. Aronson LI, Davies FE. DangER: protein overload. Targeting protein degradation to treat myeloma. Haematologica 2012;97:1119-30
12. Jankowska E, Stoj J, Karpowicz P, et al. The proteasome in health and disease. Curr Pharm Des 2013;19:1010-28
13. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
14. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64
15. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19
16. Kane RC, Farrell A, Sridhara R, et al. United States Food and Drug Administration Approval Summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955-60
17. Qiang YW, Heuck CJ, Shaughnessy JD, et al. Proteasome inhibitors and bone disease. Semin Hematol 2012;49:243-8
18. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-3
19. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
20. Kumar SK, Dispenzieri A, Gertz MA, et al. Continued improvement in survival in multiple myeloma and the impact of novel agents. Blood 2012;120:abstract 3972
21. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85
22. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-8
23. Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-53
24. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-4
25. Kyprolis [package insert]. Onyx Pharmaceuticals, South San Francisco, CA; 2012
26. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6
27. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
28. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91
29. Groll M, Kim KB, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis of α′, β′-epoxyketone proteasome inhibitors. J Am Chem Soc 2000;122:1237-8
30. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8
31. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011;17:2734-43
32. Demo SD, Buchholz TJ, Laidig GJ, et al. Biochemical and cellular characterization of the novel proteasome inhibitor PR-171. Blood 2005;106:abstract 1588
33. Stapnes C, Døskeland AP, Hatfield K, et al. The proteasome inhbitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136:814-28
34. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-roteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90
35. Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011;39:1873-82
36. Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-rug interaction of carfilzomib. Drug Metab Dispos 2013;41:230-7
37. Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012;18:4830-40
38. Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013;27:1707-14
39. Vozniak JM. Carfilzomib. J Adv Pract Oncol 2013;4(Suppl 1):15-21
40. Vij R, Siegel D, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158:739-48
41. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012;119:5661-70
42. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-25
43. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012;26:149-57
44. Papadopoulos KP, Siegel DS, Vesole DH, et al. A phase 1 study of 30-minute infusion of single-agent carfilzomib or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol 2014; In press
45. Berenson JR, Klein L, Rifkin RM, et al. A phase 1, dose-escalation study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma [abstract 1934]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
46. Berenson JR, Klein L, Rifkin RM, et al. Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma [abstract 8594]. Presented at: annual Meeting of the American Society of Clinical Oncology (ASCO); May 30 - June 3 2014; Chicago, Illinois
47. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
48. Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014;123:1461-9
49. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-19
50. Richardson PG, Jagannath S, Jakubowiak AJ, et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up. Blood 2010;116:abstract 3049
51. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
52. Niesvizky R, Martin TG III, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013;19:2248-56
53. Jakubowiak AJ. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev 2014;40:781-90
54. Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:3122-8
55. Shah JJ, Stadtmauer EA, Abonour R, et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (car-pom-d) in patients with relapsed/refractory multiple myeloma [abstract 690]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
56. Sanchez E, Li M, Li J, et al. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leuk Res 2012;36:1422-7
57. Berenson JR, Hilger JD, Yellin O, et al. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia 2014;28(7):1529-36
58. Berdeja JG, Savona M, Mace JR, et al. A single-arm, open-label, multi-center phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapse/refractory multiple myeloma. 2013 ASH Annual Meeting; New Orleans. Blood 2013;122:abstract 1937
59. Shah JJ, Thomas S, Weber D, et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma [abstract 4081]. Presented at: 54th Annual Meeting of the American Society of Hematology (ASH); 8-11 December 2012; Atlanta, Georgia
60. Vesole DH, Bilotti E, Richter JR, et al. Phase I study of carfilzomib, lenalidomide, vorinostat and dexamethasone (QUAD) in relapsed +/- refractory multiple myeloma [abstract 8535]. Presented at: annual Meeting of the American Society of Clinical Oncology (ASCO); May 30 - June 3 2014; Chicago, Illinois
61. Lonial S, Shah JJ, Zonder J, et al. Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a phase 2 study [abstract 285]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
62. Woessner R, Tunquist B, Cox A, et al. Combination of the KSP inhibitor ARRY-520 with bortezomib or revlimid causes sustained tumor regressions and significantly increased time to regrowth in models of multiple myeloma [abstract 2858]. Presented at: 51st Annual Meeting of the American Society of Hematology (ASH); 5-8 December 2013; New Orleans, Louisiana; 2009
63. Shah JJ, Feng L, Thomas S, et al. Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 (filanesib) + carfilzomib (car) in patients with relapsed and/or refractory multiple myeloma (RRMM) [abstract 1982]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
64. Gay F, Rajkumar SV, Coleman M, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010;85:664-9
65. Mark TM, Allan JN, Marano G, et al. Car-bird [carfilzomib, clarithromycin (biaxin®), lenalidomide/(revlimid®), dexamethasone) for newly-diagnosed multiple myeloma. Blood 2013;122:abstract 3216
66. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and lowdose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801-9
67. Korde N, Landgren O. Phase II: carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma [abstract 538]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
68. Sonneveld P, Asselberg-Hacker E, Zweegman S, et al. Dose escalation phase 2 trial of carfilzomib combined with thalidomide and low-dose dexamethasone in newly diagnosed, transplant eligible patients with multiple myeloma. A trial of the european myeloma network. Blood 2013;122:abstract 688
69. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101-9
70. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014;32:634-40
71. Mikhael J, Reeder C, Libby E, et al. A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma: final results of MTD expansion cohort [abstract 3179]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
72. Moreau P, Kolb B, Hulin C, et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP) in response rates in elderly patients with newly diagnosed multiple myeloma: results of a phase I/II trial [abstract 1933]. Presented at: 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 December 2013; New Orleans, Louisiana
73. Morgan GJ, Davies FE, Gregory WM, et al. NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231-8
74. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82
75. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124:63-9
76. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98:1753-61
77. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010;95:311-19
78. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608
79. Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology 2013;27(Suppl 3):4-10
80. Shah JJ. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology 2013;27(Suppl 3):19-23
81. Wang M, Cheng J. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology 2013;27(Suppl 3):24-30
82. Kaufman J, Siegel D, Vij R, et al. Clinical profile of once-daily, modified-release oprozomib tablets in patients with hematologic malignancies: results of a phase 1b/2 trial. Haematologica 2013;98(Suppl 1):abstract P233
83. Ghobrial IM, Kaufman JL, Siegel DS, et al. Clinical profile of single-agent modified-release oprozomib tablets in patients (pts) with hematologic malignancies: updated results from a multicenter, open-label, dose escalation phase 1b/2 study. Blood 2013;122:abstract 3184
84. Kumar SK, Roy V, Reeder C, et al. Phase 2 trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib. Blood 2013;122:abstract 1944
85. Richardson P, Berdeja JG, Niesvizy R, et al. Weekly oral investigational proteasome inhibitor MLN9708 plus lenalidomide-dexamethasone in elderly patients (pts) with previously untreated multiple myeloma (mm): subset analysis of a phase 1/2 study. Haematologica 2013;98(Suppl 1):abstract P236
86. Richardson PG, Hofmeister CC, Rosenbaum CA, et al. Twice-weekly oral MLN9708 (ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (dex) in patients (pts) with newly diagnosed multiple myeloma (mm): final phase 1 results and phase 2 data. Blood 2013;122:abstract 535
87. Shah JJ, Baladandayuthapani V, Weber DM, et al. Phase II study of the combination of MLN 9708 with lenalidomide as maintenance therapy post autologous stem cell transplant in patients with multiple myeloma. Blood 2013;122:abstract 1983
88. Kuroda J, Nagoshi H, Shimura Y, et al. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther 2013;13:1081-8
89. Martin TG, Hsu K, Strickland SA, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol 2014;32:abstract 8532
90. Kubiczkova L, Pour L, Sedlarikova L, et al. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014;18:947-61
91. Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res 2014;38:1-9
92. Laubach JP, Tai YT, Richardson PG, et al. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs 2014;23:445-52
93. Lonial S, Kaufman J, Laubach J, Richardson P. Elotuzumab: a novel anti- CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther 2013;13:1731-40
94. Marteijn JAF, Jansen JH, van der Reijden BA. Ubiquitylation in normal and malignant hematopoiesis: novel therapeutic targets. Leukemia 2006;20:1511-18
95. ACD/ChemSketch Freeware. Advanced Chemistry Development, Inc, Toronto, ON, Canada; 2014. Available from: www.acdlabs.com